nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0746	0.279	CbGbCtD
Trifluoperazine—ABCB1—Betamethasone—ankylosing spondylitis	0.0485	0.182	CbGbCtD
Trifluoperazine—ABCB1—Prednisolone—ankylosing spondylitis	0.0479	0.179	CbGbCtD
Trifluoperazine—ABCB1—Prednisone—ankylosing spondylitis	0.0452	0.169	CbGbCtD
Trifluoperazine—ABCB1—Dexamethasone—ankylosing spondylitis	0.0282	0.106	CbGbCtD
Trifluoperazine—ABCB1—Methotrexate—ankylosing spondylitis	0.0227	0.0849	CbGbCtD
Trifluoperazine—Pigmentation skin—Prednisone—ankylosing spondylitis	0.0199	0.0434	CcSEcCtD
Trifluoperazine—Megacolon—Methotrexate—ankylosing spondylitis	0.0185	0.0404	CcSEcCtD
Trifluoperazine—Pigmentation disorder—Prednisone—ankylosing spondylitis	0.0109	0.0237	CcSEcCtD
Trifluoperazine—Menstruation irregular—Prednisolone—ankylosing spondylitis	0.00905	0.0197	CcSEcCtD
Trifluoperazine—S100A4—Desoximetasone—Methylprednisolone—ankylosing spondylitis	0.00859	0.174	CbGdCrCtD
Trifluoperazine—Retinal disorder—Methotrexate—ankylosing spondylitis	0.00852	0.0185	CcSEcCtD
Trifluoperazine—S100A4—Desoximetasone—Betamethasone—ankylosing spondylitis	0.00845	0.172	CbGdCrCtD
Trifluoperazine—S100A4—Desoximetasone—Dexamethasone—ankylosing spondylitis	0.00845	0.172	CbGdCrCtD
Trifluoperazine—Systemic lupus erythematosus—Triamcinolone—ankylosing spondylitis	0.00832	0.0181	CcSEcCtD
Trifluoperazine—Menstruation irregular—Triamcinolone—ankylosing spondylitis	0.00832	0.0181	CcSEcCtD
Trifluoperazine—Menstruation irregular—Methylprednisolone—ankylosing spondylitis	0.0083	0.0181	CcSEcCtD
Trifluoperazine—S100A4—Desoximetasone—Triamcinolone—ankylosing spondylitis	0.00826	0.168	CbGdCrCtD
Trifluoperazine—S100A4—Desoximetasone—Prednisone—ankylosing spondylitis	0.00784	0.159	CbGdCrCtD
Trifluoperazine—S100A4—Desoximetasone—Prednisolone—ankylosing spondylitis	0.00765	0.155	CbGdCrCtD
Trifluoperazine—Menstruation irregular—Betamethasone—ankylosing spondylitis	0.00755	0.0164	CcSEcCtD
Trifluoperazine—Menstruation irregular—Dexamethasone—ankylosing spondylitis	0.00755	0.0164	CcSEcCtD
Trifluoperazine—Menstruation irregular—Prednisone—ankylosing spondylitis	0.00657	0.0143	CcSEcCtD
Trifluoperazine—Mydriasis—Prednisolone—ankylosing spondylitis	0.00628	0.0137	CcSEcCtD
Trifluoperazine—Sudden death—Methotrexate—ankylosing spondylitis	0.00594	0.0129	CcSEcCtD
Trifluoperazine—Glycosuria—Triamcinolone—ankylosing spondylitis	0.00569	0.0124	CcSEcCtD
Trifluoperazine—Glycosuria—Methylprednisolone—ankylosing spondylitis	0.00567	0.0124	CcSEcCtD
Trifluoperazine—Amenorrhoea—Methylprednisolone—ankylosing spondylitis	0.00523	0.0114	CcSEcCtD
Trifluoperazine—Glycosuria—Dexamethasone—ankylosing spondylitis	0.00516	0.0112	CcSEcCtD
Trifluoperazine—Glycosuria—Betamethasone—ankylosing spondylitis	0.00516	0.0112	CcSEcCtD
Trifluoperazine—Amenorrhoea—Betamethasone—ankylosing spondylitis	0.00476	0.0104	CcSEcCtD
Trifluoperazine—Amenorrhoea—Dexamethasone—ankylosing spondylitis	0.00476	0.0104	CcSEcCtD
Trifluoperazine—Glycosuria—Prednisone—ankylosing spondylitis	0.00449	0.00978	CcSEcCtD
Trifluoperazine—Amenorrhoea—Prednisone—ankylosing spondylitis	0.00414	0.00902	CcSEcCtD
Trifluoperazine—Increased appetite—Prednisolone—ankylosing spondylitis	0.00387	0.00843	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Prednisolone—ankylosing spondylitis	0.00376	0.00818	CcSEcCtD
Trifluoperazine—Increased appetite—Triamcinolone—ankylosing spondylitis	0.00356	0.00775	CcSEcCtD
Trifluoperazine—Increased appetite—Methylprednisolone—ankylosing spondylitis	0.00355	0.00773	CcSEcCtD
Trifluoperazine—Cardiac arrest—Prednisolone—ankylosing spondylitis	0.00346	0.00753	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Triamcinolone—ankylosing spondylitis	0.00345	0.00752	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Methylprednisolone—ankylosing spondylitis	0.00345	0.00751	CcSEcCtD
Trifluoperazine—Increased appetite—Dexamethasone—ankylosing spondylitis	0.00323	0.00703	CcSEcCtD
Trifluoperazine—Increased appetite—Betamethasone—ankylosing spondylitis	0.00323	0.00703	CcSEcCtD
Trifluoperazine—Muscular weakness—Prednisolone—ankylosing spondylitis	0.00321	0.00698	CcSEcCtD
Trifluoperazine—Cardiac arrest—Triamcinolone—ankylosing spondylitis	0.00318	0.00692	CcSEcCtD
Trifluoperazine—Cardiac arrest—Methylprednisolone—ankylosing spondylitis	0.00317	0.00691	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Betamethasone—ankylosing spondylitis	0.00313	0.00683	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Dexamethasone—ankylosing spondylitis	0.00313	0.00683	CcSEcCtD
Trifluoperazine—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.00295	0.00642	CcSEcCtD
Trifluoperazine—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.00294	0.00641	CcSEcCtD
Trifluoperazine—Asthma—Triamcinolone—ankylosing spondylitis	0.00289	0.00629	CcSEcCtD
Trifluoperazine—Cardiac arrest—Betamethasone—ankylosing spondylitis	0.00288	0.00628	CcSEcCtD
Trifluoperazine—Cardiac arrest—Dexamethasone—ankylosing spondylitis	0.00288	0.00628	CcSEcCtD
Trifluoperazine—Weight increased—Prednisolone—ankylosing spondylitis	0.00286	0.00623	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Methotrexate—ankylosing spondylitis	0.00286	0.00622	CcSEcCtD
Trifluoperazine—Bronchospasm—Methylprednisolone—ankylosing spondylitis	0.00284	0.00618	CcSEcCtD
Trifluoperazine—Increased appetite—Prednisone—ankylosing spondylitis	0.00281	0.00612	CcSEcCtD
Trifluoperazine—Gynaecomastia—Methotrexate—ankylosing spondylitis	0.00272	0.00593	CcSEcCtD
Trifluoperazine—Muscular weakness—Betamethasone—ankylosing spondylitis	0.00268	0.00583	CcSEcCtD
Trifluoperazine—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.00268	0.00583	CcSEcCtD
Trifluoperazine—Weight increased—Triamcinolone—ankylosing spondylitis	0.00263	0.00573	CcSEcCtD
Trifluoperazine—Weight increased—Methylprednisolone—ankylosing spondylitis	0.00262	0.00571	CcSEcCtD
Trifluoperazine—Photosensitivity—Methotrexate—ankylosing spondylitis	0.00251	0.00548	CcSEcCtD
Trifluoperazine—Cardiac arrest—Prednisone—ankylosing spondylitis	0.00251	0.00547	CcSEcCtD
Trifluoperazine—Weight increased—Dexamethasone—ankylosing spondylitis	0.00239	0.0052	CcSEcCtD
Trifluoperazine—Weight increased—Betamethasone—ankylosing spondylitis	0.00239	0.0052	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.00237	0.00515	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.00237	0.00515	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.00234	0.0051	CcSEcCtD
Trifluoperazine—Muscular weakness—Prednisone—ankylosing spondylitis	0.00233	0.00507	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Methotrexate—ankylosing spondylitis	0.00228	0.00497	CcSEcCtD
Trifluoperazine—CALM3—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00225	0.01	CbGpPWpGaD
Trifluoperazine—Erythema—Prednisolone—ankylosing spondylitis	0.00219	0.00477	CcSEcCtD
Trifluoperazine—CALM2—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00218	0.00971	CbGpPWpGaD
Trifluoperazine—CALM1—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00218	0.00971	CbGpPWpGaD
Trifluoperazine—CALM2—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00217	0.00966	CbGpPWpGaD
Trifluoperazine—CALM1—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00217	0.00966	CbGpPWpGaD
Trifluoperazine—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.0021	0.00458	CcSEcCtD
Trifluoperazine—CALM3—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00209	0.00929	CbGpPWpGaD
Trifluoperazine—Weight increased—Prednisone—ankylosing spondylitis	0.00208	0.00453	CcSEcCtD
Trifluoperazine—XDH—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.00208	0.00925	CbGpPWpGaD
Trifluoperazine—Vision blurred—Prednisolone—ankylosing spondylitis	0.00206	0.00449	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.00206	0.00449	CcSEcCtD
Trifluoperazine—CALM1—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00202	0.00899	CbGpPWpGaD
Trifluoperazine—CALM2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00202	0.00899	CbGpPWpGaD
Trifluoperazine—Erythema—Triamcinolone—ankylosing spondylitis	0.00201	0.00438	CcSEcCtD
Trifluoperazine—Erythema—Methylprednisolone—ankylosing spondylitis	0.00201	0.00437	CcSEcCtD
Trifluoperazine—Angioedema—Prednisolone—ankylosing spondylitis	0.002	0.00436	CcSEcCtD
Trifluoperazine—Asthma—Methotrexate—ankylosing spondylitis	0.00191	0.00416	CcSEcCtD
Trifluoperazine—Convulsion—Prednisolone—ankylosing spondylitis	0.0019	0.00413	CcSEcCtD
Trifluoperazine—Eosinophilia—Methotrexate—ankylosing spondylitis	0.00189	0.00411	CcSEcCtD
Trifluoperazine—Angioedema—Triamcinolone—ankylosing spondylitis	0.00184	0.00401	CcSEcCtD
Trifluoperazine—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00184	0.004	CcSEcCtD
Trifluoperazine—HTR6—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.00184	0.00818	CbGpPWpGaD
Trifluoperazine—Erythema—Dexamethasone—ankylosing spondylitis	0.00183	0.00398	CcSEcCtD
Trifluoperazine—Erythema—Betamethasone—ankylosing spondylitis	0.00183	0.00398	CcSEcCtD
Trifluoperazine—Pancytopenia—Methotrexate—ankylosing spondylitis	0.00181	0.00395	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00179	0.00389	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.00176	0.00383	CcSEcCtD
Trifluoperazine—Cough—Triamcinolone—ankylosing spondylitis	0.00176	0.00383	CcSEcCtD
Trifluoperazine—Convulsion—Triamcinolone—ankylosing spondylitis	0.00174	0.0038	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.00174	0.00379	CcSEcCtD
Trifluoperazine—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00174	0.00379	CcSEcCtD
Trifluoperazine—Drowsiness—Methotrexate—ankylosing spondylitis	0.0017	0.00371	CcSEcCtD
Trifluoperazine—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00168	0.00365	CcSEcCtD
Trifluoperazine—Angioedema—Dexamethasone—ankylosing spondylitis	0.00167	0.00364	CcSEcCtD
Trifluoperazine—Angioedema—Betamethasone—ankylosing spondylitis	0.00167	0.00364	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00164	0.00358	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00164	0.00357	CcSEcCtD
Trifluoperazine—Insomnia—Prednisolone—ankylosing spondylitis	0.00162	0.00352	CcSEcCtD
Trifluoperazine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00159	0.00347	CcSEcCtD
Trifluoperazine—Erythema—Prednisone—ankylosing spondylitis	0.00159	0.00346	CcSEcCtD
Trifluoperazine—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.00159	0.00346	CcSEcCtD
Trifluoperazine—Convulsion—Betamethasone—ankylosing spondylitis	0.00158	0.00345	CcSEcCtD
Trifluoperazine—Convulsion—Dexamethasone—ankylosing spondylitis	0.00158	0.00345	CcSEcCtD
Trifluoperazine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.00158	0.00703	CbGpPWpGaD
Trifluoperazine—HTR1A—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.00153	0.00683	CbGpPWpGaD
Trifluoperazine—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00153	0.00334	CcSEcCtD
Trifluoperazine—Vision blurred—Prednisone—ankylosing spondylitis	0.0015	0.00327	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00149	0.00325	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00149	0.00325	CcSEcCtD
Trifluoperazine—Insomnia—Triamcinolone—ankylosing spondylitis	0.00149	0.00324	CcSEcCtD
Trifluoperazine—Insomnia—Methylprednisolone—ankylosing spondylitis	0.00148	0.00323	CcSEcCtD
Trifluoperazine—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00146	0.00319	CcSEcCtD
Trifluoperazine—Agitation—Prednisone—ankylosing spondylitis	0.00146	0.00318	CcSEcCtD
Trifluoperazine—Angioedema—Prednisone—ankylosing spondylitis	0.00145	0.00317	CcSEcCtD
Trifluoperazine—Anorexia—Betamethasone—ankylosing spondylitis	0.00142	0.0031	CcSEcCtD
Trifluoperazine—Anorexia—Dexamethasone—ankylosing spondylitis	0.00142	0.0031	CcSEcCtD
Trifluoperazine—Urticaria—Prednisolone—ankylosing spondylitis	0.00142	0.00309	CcSEcCtD
Trifluoperazine—Fatigue—Triamcinolone—ankylosing spondylitis	0.00142	0.00309	CcSEcCtD
Trifluoperazine—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00141	0.00308	CcSEcCtD
Trifluoperazine—Hypotension—Dexamethasone—ankylosing spondylitis	0.00139	0.00303	CcSEcCtD
Trifluoperazine—Hypotension—Betamethasone—ankylosing spondylitis	0.00139	0.00303	CcSEcCtD
Trifluoperazine—Convulsion—Prednisone—ankylosing spondylitis	0.00138	0.003	CcSEcCtD
Trifluoperazine—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00135	0.00601	CbGpPWpGaD
Trifluoperazine—Insomnia—Betamethasone—ankylosing spondylitis	0.00135	0.00294	CcSEcCtD
Trifluoperazine—Insomnia—Dexamethasone—ankylosing spondylitis	0.00135	0.00294	CcSEcCtD
Trifluoperazine—Erythema—Methotrexate—ankylosing spondylitis	0.00133	0.0029	CcSEcCtD
Trifluoperazine—HTR2A—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.00132	0.0059	CbGpPWpGaD
Trifluoperazine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00132	0.00287	CcSEcCtD
Trifluoperazine—CALM3—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00131	0.00583	CbGpPWpGaD
Trifluoperazine—Urticaria—Triamcinolone—ankylosing spondylitis	0.00131	0.00284	CcSEcCtD
Trifluoperazine—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.0013	0.00581	CbGpPWpGaD
Trifluoperazine—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.0013	0.00581	CbGpPWpGaD
Trifluoperazine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.0013	0.00284	CcSEcCtD
Trifluoperazine—CHRM2—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.0013	0.00579	CbGpPWpGaD
Trifluoperazine—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.0013	0.00283	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.0013	0.00283	CcSEcCtD
Trifluoperazine—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.0013	0.00282	CcSEcCtD
Trifluoperazine—Decreased appetite—Betamethasone—ankylosing spondylitis	0.0013	0.00282	CcSEcCtD
Trifluoperazine—Fatigue—Dexamethasone—ankylosing spondylitis	0.00129	0.0028	CcSEcCtD
Trifluoperazine—Fatigue—Betamethasone—ankylosing spondylitis	0.00129	0.0028	CcSEcCtD
Trifluoperazine—CALM2—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00127	0.00564	CbGpPWpGaD
Trifluoperazine—CALM1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00127	0.00564	CbGpPWpGaD
Trifluoperazine—Skin disorder—Prednisone—ankylosing spondylitis	0.00126	0.00275	CcSEcCtD
Trifluoperazine—Vision blurred—Methotrexate—ankylosing spondylitis	0.00125	0.00273	CcSEcCtD
Trifluoperazine—Anorexia—Prednisone—ankylosing spondylitis	0.00124	0.0027	CcSEcCtD
Trifluoperazine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00121	0.00264	CcSEcCtD
Trifluoperazine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00121	0.00263	CcSEcCtD
Trifluoperazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00119	0.00532	CbGpPWpGaD
Trifluoperazine—Leukopenia—Methotrexate—ankylosing spondylitis	0.00119	0.00259	CcSEcCtD
Trifluoperazine—Urticaria—Betamethasone—ankylosing spondylitis	0.00118	0.00258	CcSEcCtD
Trifluoperazine—Urticaria—Dexamethasone—ankylosing spondylitis	0.00118	0.00258	CcSEcCtD
Trifluoperazine—Dizziness—Prednisolone—ankylosing spondylitis	0.00118	0.00257	CcSEcCtD
Trifluoperazine—Asthenia—Triamcinolone—ankylosing spondylitis	0.00118	0.00257	CcSEcCtD
Trifluoperazine—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00118	0.00257	CcSEcCtD
Trifluoperazine—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00118	0.00257	CcSEcCtD
Trifluoperazine—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00118	0.00256	CcSEcCtD
Trifluoperazine—Insomnia—Prednisone—ankylosing spondylitis	0.00117	0.00256	CcSEcCtD
Trifluoperazine—Pruritus—Triamcinolone—ankylosing spondylitis	0.00116	0.00253	CcSEcCtD
Trifluoperazine—Cough—Methotrexate—ankylosing spondylitis	0.00116	0.00253	CcSEcCtD
Trifluoperazine—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00116	0.00253	CcSEcCtD
Trifluoperazine—Convulsion—Methotrexate—ankylosing spondylitis	0.00115	0.00251	CcSEcCtD
Trifluoperazine—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00114	0.00508	CbGpPWpGaD
Trifluoperazine—Decreased appetite—Prednisone—ankylosing spondylitis	0.00113	0.00246	CcSEcCtD
Trifluoperazine—Rash—Prednisolone—ankylosing spondylitis	0.00113	0.00245	CcSEcCtD
Trifluoperazine—Dermatitis—Prednisolone—ankylosing spondylitis	0.00113	0.00245	CcSEcCtD
Trifluoperazine—Fatigue—Prednisone—ankylosing spondylitis	0.00112	0.00244	CcSEcCtD
Trifluoperazine—Headache—Prednisolone—ankylosing spondylitis	0.00112	0.00244	CcSEcCtD
Trifluoperazine—Constipation—Prednisone—ankylosing spondylitis	0.00111	0.00242	CcSEcCtD
Trifluoperazine—Dizziness—Triamcinolone—ankylosing spondylitis	0.00109	0.00237	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00109	0.00236	CcSEcCtD
Trifluoperazine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00108	0.00236	CcSEcCtD
Trifluoperazine—Asthenia—Dexamethasone—ankylosing spondylitis	0.00107	0.00233	CcSEcCtD
Trifluoperazine—Asthenia—Betamethasone—ankylosing spondylitis	0.00107	0.00233	CcSEcCtD
Trifluoperazine—Nausea—Prednisolone—ankylosing spondylitis	0.00106	0.00231	CcSEcCtD
Trifluoperazine—HTR1A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.00106	0.00471	CbGpPWpGaD
Trifluoperazine—Pruritus—Betamethasone—ankylosing spondylitis	0.00105	0.0023	CcSEcCtD
Trifluoperazine—Pruritus—Dexamethasone—ankylosing spondylitis	0.00105	0.0023	CcSEcCtD
Trifluoperazine—Skin disorder—Methotrexate—ankylosing spondylitis	0.00105	0.0023	CcSEcCtD
Trifluoperazine—EBP—Metabolism—B3GNT2—ankylosing spondylitis	0.00104	0.00465	CbGpPWpGaD
Trifluoperazine—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.00104	0.00465	CbGpPWpGaD
Trifluoperazine—Rash—Triamcinolone—ankylosing spondylitis	0.00104	0.00226	CcSEcCtD
Trifluoperazine—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00104	0.00225	CcSEcCtD
Trifluoperazine—Anorexia—Methotrexate—ankylosing spondylitis	0.00103	0.00225	CcSEcCtD
Trifluoperazine—Rash—Methylprednisolone—ankylosing spondylitis	0.00103	0.00225	CcSEcCtD
Trifluoperazine—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00103	0.00225	CcSEcCtD
Trifluoperazine—Urticaria—Prednisone—ankylosing spondylitis	0.00103	0.00225	CcSEcCtD
Trifluoperazine—Headache—Triamcinolone—ankylosing spondylitis	0.00103	0.00224	CcSEcCtD
Trifluoperazine—Headache—Methylprednisolone—ankylosing spondylitis	0.00103	0.00224	CcSEcCtD
Trifluoperazine—Body temperature increased—Prednisone—ankylosing spondylitis	0.00103	0.00224	CcSEcCtD
Trifluoperazine—HTR6—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00102	0.00455	CbGpPWpGaD
Trifluoperazine—Hypotension—Methotrexate—ankylosing spondylitis	0.00101	0.00221	CcSEcCtD
Trifluoperazine—CALM3—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.00099	0.00441	CbGpPWpGaD
Trifluoperazine—Dizziness—Betamethasone—ankylosing spondylitis	0.000986	0.00215	CcSEcCtD
Trifluoperazine—Dizziness—Dexamethasone—ankylosing spondylitis	0.000986	0.00215	CcSEcCtD
Trifluoperazine—Insomnia—Methotrexate—ankylosing spondylitis	0.000981	0.00214	CcSEcCtD
Trifluoperazine—Nausea—Triamcinolone—ankylosing spondylitis	0.000976	0.00213	CcSEcCtD
Trifluoperazine—Nausea—Methylprednisolone—ankylosing spondylitis	0.000974	0.00212	CcSEcCtD
Trifluoperazine—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.00097	0.00432	CbGpPWpGaD
Trifluoperazine—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000967	0.00211	CcSEcCtD
Trifluoperazine—Somnolence—Methotrexate—ankylosing spondylitis	0.000965	0.0021	CcSEcCtD
Trifluoperazine—CALM1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000958	0.00427	CbGpPWpGaD
Trifluoperazine—CALM2—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000958	0.00427	CbGpPWpGaD
Trifluoperazine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000957	0.00208	CcSEcCtD
Trifluoperazine—CALM3—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000952	0.00424	CbGpPWpGaD
Trifluoperazine—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000943	0.00205	CcSEcCtD
Trifluoperazine—Rash—Betamethasone—ankylosing spondylitis	0.00094	0.00205	CcSEcCtD
Trifluoperazine—Rash—Dexamethasone—ankylosing spondylitis	0.00094	0.00205	CcSEcCtD
Trifluoperazine—XDH—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000939	0.00419	CbGpPWpGaD
Trifluoperazine—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000939	0.00205	CcSEcCtD
Trifluoperazine—Dermatitis—Betamethasone—ankylosing spondylitis	0.000939	0.00205	CcSEcCtD
Trifluoperazine—Fatigue—Methotrexate—ankylosing spondylitis	0.000936	0.00204	CcSEcCtD
Trifluoperazine—Headache—Dexamethasone—ankylosing spondylitis	0.000934	0.00203	CcSEcCtD
Trifluoperazine—Headache—Betamethasone—ankylosing spondylitis	0.000934	0.00203	CcSEcCtD
Trifluoperazine—Asthenia—Prednisone—ankylosing spondylitis	0.000932	0.00203	CcSEcCtD
Trifluoperazine—CALM1—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000921	0.0041	CbGpPWpGaD
Trifluoperazine—CALM2—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000921	0.0041	CbGpPWpGaD
Trifluoperazine—Pruritus—Prednisone—ankylosing spondylitis	0.000919	0.002	CcSEcCtD
Trifluoperazine—HTR2A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000914	0.00407	CbGpPWpGaD
Trifluoperazine—CHRM2—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000897	0.004	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000893	0.00398	CbGpPWpGaD
Trifluoperazine—Nausea—Dexamethasone—ankylosing spondylitis	0.000886	0.00193	CcSEcCtD
Trifluoperazine—Nausea—Betamethasone—ankylosing spondylitis	0.000886	0.00193	CcSEcCtD
Trifluoperazine—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000875	0.0039	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000863	0.00385	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000863	0.00385	CbGpPWpGaD
Trifluoperazine—Urticaria—Methotrexate—ankylosing spondylitis	0.000862	0.00188	CcSEcCtD
Trifluoperazine—Dizziness—Prednisone—ankylosing spondylitis	0.000859	0.00187	CcSEcCtD
Trifluoperazine—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000858	0.00187	CcSEcCtD
Trifluoperazine—Rash—Prednisone—ankylosing spondylitis	0.000819	0.00178	CcSEcCtD
Trifluoperazine—Dermatitis—Prednisone—ankylosing spondylitis	0.000818	0.00178	CcSEcCtD
Trifluoperazine—Headache—Prednisone—ankylosing spondylitis	0.000813	0.00177	CcSEcCtD
Trifluoperazine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000799	0.00174	CcSEcCtD
Trifluoperazine—CALM3—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000789	0.00352	CbGpPWpGaD
Trifluoperazine—CALM3—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000788	0.00351	CbGpPWpGaD
Trifluoperazine—Asthenia—Methotrexate—ankylosing spondylitis	0.000779	0.0017	CcSEcCtD
Trifluoperazine—Nausea—Prednisone—ankylosing spondylitis	0.000771	0.00168	CcSEcCtD
Trifluoperazine—Pruritus—Methotrexate—ankylosing spondylitis	0.000768	0.00167	CcSEcCtD
Trifluoperazine—CALM1—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000763	0.0034	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000763	0.0034	CbGpPWpGaD
Trifluoperazine—CALM1—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000762	0.0034	CbGpPWpGaD
Trifluoperazine—CALM2—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000762	0.0034	CbGpPWpGaD
Trifluoperazine—HTR1A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000761	0.00339	CbGpPWpGaD
Trifluoperazine—HTR1A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000757	0.00337	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000756	0.00337	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000752	0.00335	CbGpPWpGaD
Trifluoperazine—Dizziness—Methotrexate—ankylosing spondylitis	0.000718	0.00156	CcSEcCtD
Trifluoperazine—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000713	0.00318	CbGpPWpGaD
Trifluoperazine—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000709	0.00316	CbGpPWpGaD
Trifluoperazine—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000709	0.00316	CbGpPWpGaD
Trifluoperazine—Rash—Methotrexate—ankylosing spondylitis	0.000684	0.00149	CcSEcCtD
Trifluoperazine—Dermatitis—Methotrexate—ankylosing spondylitis	0.000684	0.00149	CcSEcCtD
Trifluoperazine—Headache—Methotrexate—ankylosing spondylitis	0.00068	0.00148	CcSEcCtD
Trifluoperazine—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000677	0.00302	CbGpPWpGaD
Trifluoperazine—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000674	0.003	CbGpPWpGaD
Trifluoperazine—HTR6—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000666	0.00297	CbGpPWpGaD
Trifluoperazine—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000664	0.00296	CbGpPWpGaD
Trifluoperazine—HTR2A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000658	0.00293	CbGpPWpGaD
Trifluoperazine—HTR2A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000654	0.00291	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000653	0.00291	CbGpPWpGaD
Trifluoperazine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000652	0.0029	CbGpPWpGaD
Trifluoperazine—HTR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000648	0.00289	CbGpPWpGaD
Trifluoperazine—CHRM2—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000646	0.00288	CbGpPWpGaD
Trifluoperazine—Nausea—Methotrexate—ankylosing spondylitis	0.000645	0.0014	CcSEcCtD
Trifluoperazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000644	0.00287	CbGpPWpGaD
Trifluoperazine—CHRM2—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000642	0.00286	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000641	0.00286	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000639	0.00285	CbGpPWpGaD
Trifluoperazine—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000625	0.00278	CbGpPWpGaD
Trifluoperazine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.00062	0.00276	CbGpPWpGaD
Trifluoperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000569	0.00253	CbGpPWpGaD
Trifluoperazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.00056	0.00249	CbGpPWpGaD
Trifluoperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000558	0.00249	CbGpPWpGaD
Trifluoperazine—CALM3—B Cell Activation—CD79A—ankylosing spondylitis	0.000557	0.00248	CbGpPWpGaD
Trifluoperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000549	0.00245	CbGpPWpGaD
Trifluoperazine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000548	0.00244	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KIR3DL1—ankylosing spondylitis	0.000541	0.00241	CbGpPWpGaD
Trifluoperazine—CALM1—B Cell Activation—CD79A—ankylosing spondylitis	0.000539	0.0024	CbGpPWpGaD
Trifluoperazine—CALM2—B Cell Activation—CD79A—ankylosing spondylitis	0.000539	0.0024	CbGpPWpGaD
Trifluoperazine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000538	0.0024	CbGpPWpGaD
Trifluoperazine—UGT1A4—Metabolism—B3GNT2—ankylosing spondylitis	0.000538	0.0024	CbGpPWpGaD
Trifluoperazine—XDH—Metabolism—B3GNT2—ankylosing spondylitis	0.000538	0.0024	CbGpPWpGaD
Trifluoperazine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000537	0.00239	CbGpPWpGaD
Trifluoperazine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000527	0.00235	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KIR3DL1—ankylosing spondylitis	0.000524	0.00233	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KIR3DL1—ankylosing spondylitis	0.000524	0.00233	CbGpPWpGaD
Trifluoperazine—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000513	0.00229	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000513	0.00228	CbGpPWpGaD
Trifluoperazine—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000497	0.00221	CbGpPWpGaD
Trifluoperazine—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000497	0.00221	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000496	0.00221	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000496	0.00221	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000493	0.0022	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000491	0.00219	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—CARD9—ankylosing spondylitis	0.000488	0.00218	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—CARD9—ankylosing spondylitis	0.000472	0.0021	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—CARD9—ankylosing spondylitis	0.000472	0.0021	CbGpPWpGaD
Trifluoperazine—CALM3—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000467	0.00208	CbGpPWpGaD
Trifluoperazine—CALM1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.00046	0.00205	CbGpPWpGaD
Trifluoperazine—CALM2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.00046	0.00205	CbGpPWpGaD
Trifluoperazine—CALM2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000451	0.00201	CbGpPWpGaD
Trifluoperazine—CALM1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000451	0.00201	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000433	0.00193	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000426	0.0019	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000425	0.00189	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000418	0.00186	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000417	0.00186	CbGpPWpGaD
Trifluoperazine—CALM3—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000411	0.00183	CbGpPWpGaD
Trifluoperazine—CALM1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000398	0.00177	CbGpPWpGaD
Trifluoperazine—CALM2—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000398	0.00177	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—ANTXR2—ankylosing spondylitis	0.000379	0.00169	CbGpPWpGaD
Trifluoperazine—HTR6—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000377	0.00168	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—ANTXR2—ankylosing spondylitis	0.000366	0.00163	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—ANTXR2—ankylosing spondylitis	0.000366	0.00163	CbGpPWpGaD
Trifluoperazine—CALM3—Alzheimers Disease—TNF—ankylosing spondylitis	0.000356	0.00159	CbGpPWpGaD
Trifluoperazine—CALM2—Alzheimers Disease—TNF—ankylosing spondylitis	0.000344	0.00153	CbGpPWpGaD
Trifluoperazine—CALM1—Alzheimers Disease—TNF—ankylosing spondylitis	0.000344	0.00153	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000342	0.00152	CbGpPWpGaD
Trifluoperazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000332	0.00148	CbGpPWpGaD
Trifluoperazine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000332	0.00148	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1R2—ankylosing spondylitis	0.000328	0.00146	CbGpPWpGaD
Trifluoperazine—CALM1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000328	0.00146	CbGpPWpGaD
Trifluoperazine—CALM2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000328	0.00146	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1R2—ankylosing spondylitis	0.000317	0.00141	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1R2—ankylosing spondylitis	0.000317	0.00141	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—ERAP1—ankylosing spondylitis	0.000311	0.00139	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—HLA-C—ankylosing spondylitis	0.000307	0.00137	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—ERAP1—ankylosing spondylitis	0.000301	0.00134	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—ERAP1—ankylosing spondylitis	0.000301	0.00134	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000297	0.00132	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000297	0.00132	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000294	0.00131	CbGpPWpGaD
Trifluoperazine—HTR1A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000288	0.00128	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000285	0.00127	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000285	0.00127	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CARD9—ankylosing spondylitis	0.000284	0.00127	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000279	0.00124	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000277	0.00124	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CARD9—ankylosing spondylitis	0.000275	0.00123	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CARD9—ankylosing spondylitis	0.000275	0.00123	CbGpPWpGaD
Trifluoperazine—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	0.00027	0.0012	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000253	0.00113	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000252	0.00112	CbGpPWpGaD
Trifluoperazine—HTR2A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000249	0.00111	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000245	0.00109	CbGpPWpGaD
Trifluoperazine—CHRM2—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000244	0.00109	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000243	0.00108	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000241	0.00107	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.00024	0.00107	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000236	0.00105	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000236	0.00105	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000225	0.001	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—B3GNT2—ankylosing spondylitis	0.000223	0.000995	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000222	0.00099	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000219	0.000974	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000218	0.000972	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000217	0.000968	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000217	0.000968	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—B3GNT2—ankylosing spondylitis	0.000216	0.000962	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—B3GNT2—ankylosing spondylitis	0.000216	0.000962	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000215	0.000957	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000214	0.000954	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000202	0.0009	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—B3GNT2—ankylosing spondylitis	0.000187	0.000833	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000183	0.000816	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000182	0.000809	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—HLA-B—ankylosing spondylitis	0.000181	0.000808	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—B3GNT2—ankylosing spondylitis	0.000181	0.000806	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—B3GNT2—ankylosing spondylitis	0.000181	0.000806	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—MMP3—ankylosing spondylitis	0.00018	0.000803	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000179	0.000799	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HLA-C—ankylosing spondylitis	0.000179	0.000796	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000177	0.000789	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000177	0.000789	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000176	0.000782	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000176	0.000782	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000175	0.000782	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000175	0.000782	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000174	0.000776	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HLA-C—ankylosing spondylitis	0.000173	0.00077	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HLA-C—ankylosing spondylitis	0.000173	0.00077	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000168	0.000751	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000168	0.000751	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000161	0.000719	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—CRP—ankylosing spondylitis	0.00016	0.000714	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000158	0.000705	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000156	0.000695	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000156	0.000695	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000156	0.000694	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000155	0.000692	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1RN—ankylosing spondylitis	0.000155	0.000691	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—CRP—ankylosing spondylitis	0.000155	0.000691	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—CRP—ankylosing spondylitis	0.000155	0.000691	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—TLR4—ankylosing spondylitis	0.000154	0.000685	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000153	0.000681	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000152	0.000679	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1RN—ankylosing spondylitis	0.00015	0.000669	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1RN—ankylosing spondylitis	0.00015	0.000669	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00015	0.000666	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000149	0.000663	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—TLR4—ankylosing spondylitis	0.000149	0.000662	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—TLR4—ankylosing spondylitis	0.000149	0.000662	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—MMP3—ankylosing spondylitis	0.000144	0.000641	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	0.000142	0.000631	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CD79A—ankylosing spondylitis	0.000136	0.000607	CbGpPWpGaD
Trifluoperazine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000133	0.000593	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CD79A—ankylosing spondylitis	0.000132	0.000587	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CD79A—ankylosing spondylitis	0.000132	0.000587	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000131	0.000585	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000129	0.000576	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000129	0.000576	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000129	0.000574	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000127	0.000565	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000126	0.000564	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000125	0.000557	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000125	0.000557	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	0.000113	0.000504	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1A—ankylosing spondylitis	0.000112	0.000498	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CD40LG—ankylosing spondylitis	0.000111	0.000495	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1A—ankylosing spondylitis	0.000108	0.000481	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1A—ankylosing spondylitis	0.000108	0.000481	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CD40LG—ankylosing spondylitis	0.000107	0.000479	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CD40LG—ankylosing spondylitis	0.000107	0.000479	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000107	0.000478	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MMP3—ankylosing spondylitis	0.000106	0.000474	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MMP3—ankylosing spondylitis	0.000106	0.000472	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HLA-B—ankylosing spondylitis	0.000106	0.000471	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000104	0.000462	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000104	0.000462	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HLA-B—ankylosing spondylitis	0.000102	0.000455	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HLA-B—ankylosing spondylitis	0.000102	0.000455	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HLA-A—ankylosing spondylitis	9.79e-05	0.000436	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HLA-A—ankylosing spondylitis	9.47e-05	0.000422	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HLA-A—ankylosing spondylitis	9.47e-05	0.000422	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MMP3—ankylosing spondylitis	9.35e-05	0.000417	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CRP—ankylosing spondylitis	9.33e-05	0.000416	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MMP3—ankylosing spondylitis	9.2e-05	0.00041	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MMP3—ankylosing spondylitis	9.18e-05	0.000409	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—HLA-A—ankylosing spondylitis	9.03e-05	0.000403	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MMP3—ankylosing spondylitis	9.03e-05	0.000402	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CRP—ankylosing spondylitis	9.03e-05	0.000402	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CRP—ankylosing spondylitis	9.03e-05	0.000402	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MMP3—ankylosing spondylitis	9.01e-05	0.000401	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—TLR4—ankylosing spondylitis	8.95e-05	0.000399	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—HLA-A—ankylosing spondylitis	8.74e-05	0.000389	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—HLA-A—ankylosing spondylitis	8.74e-05	0.000389	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—TLR4—ankylosing spondylitis	8.66e-05	0.000386	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—TLR4—ankylosing spondylitis	8.66e-05	0.000386	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MMP3—ankylosing spondylitis	7.63e-05	0.00034	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MMP3—ankylosing spondylitis	7.39e-05	0.000329	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MMP3—ankylosing spondylitis	7.39e-05	0.000329	CbGpPWpGaD
